About the Authors
- Hanna Nohynek
-
* E-mail: hanna.nohynek@thl.fi
Affiliation Department of Vaccines and Immune Protection, National Institute for Health and Welfare, Helsinki, Finland
- Jukka Jokinen
-
Affiliation Department of Vaccines and Immune Protection, National Institute for Health and Welfare, Helsinki, Finland
- Markku Partinen
-
Affiliation Helsinki Sleep Clinic, Vitalmed Research Centre, Helsinki, Finland
- Outi Vaarala
-
Affiliation Department of Vaccines and Immune Protection, National Institute for Health and Welfare, Helsinki, Finland
- Turkka Kirjavainen
-
Affiliation Department of Pediatrics, Children's Hospital, Helsinki University Hospital, Helsinki, Finland
- Jonas Sundman
-
Affiliation Department of Vaccines and Immune Protection, National Institute for Health and Welfare, Helsinki, Finland
- Sari-Leena Himanen
-
Affiliation Department of Clinical Neurophysiology, Tampere University Hospital, Tampere, Finland
- Christer Hublin
-
Affiliation Finnish Institute of Occupational Health, Helsinki, Finland
- Ilkka Julkunen
-
Affiliation Department of Infectious Disease Surveillance and Control, National Institute for Health and Welfare, Helsinki, Finland
- Päivi Olsén
-
Affiliation Department of Child Neurology, Oulu University Hospital, Oulu, Finland
- Outi Saarenpää-Heikkilä
-
Affiliation Department of Pediatrics, Tampere University Hospital, Tampere, Finland
- Terhi Kilpi
-
Affiliation Department of Vaccines and Immune Protection, National Institute for Health and Welfare, Helsinki, Finland
Competing Interests
HN received honoraria for technical consultancy from GlaxoSmithKline (GSK), and Pfizer for development of pneumococcal conjugate vaccines. JJ is co-investigator of a nationwide effectiveness study of the ten-valent pneumococcal conjugate vaccine mainly funded by GlaxoSmithKline. MP has been consultant for Bioprojet and UCB Pharma and received funding support and travel grants from Boehringer-Ingelheim, Bioprojet, GSK, Cephalin, MSD, Leiras and Servier. T. Kilpi is principal investigator of a nationwide effectiveness study of the ten-valent pneumococcal conjugate vaccine mainly funded by GlaxoSmithKline, and her unit received funding for a clinical trial on the safety and immunogenicity of a prototype pandemic influenza vaccine from Solvay Pharmaceuticals. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials. All other authors confirm they have no conflicts of interest.
Author Contributions
Conceived and designed the experiments: JJ T. Kilpi HN. Analyzed the data: JJ T. Kilpi HN. Contributed reagents/materials/analysis tools: JJ JS. Wrote the paper: HN JJ MP OV T. Kirjavainen JS SLH CH IJ PO OSH T. Kilpi. Designed the database: JJ JS. Obtained permissions: JJ HN T. Kilpi. Obtained data: JJ JS HN. Validated cases: MP T. Kirjavainen PO SLH OSH CH.